Dataset Information

GmFT2a polymorphism and maturity diversity in soybeans.

ABSTRACT:

Background

Soybean is a short-day crop of agricultural, ecological, and economic importance. The sensitive photoperiod responses significantly limit its breeding and adaptation. GmFT2a, a putative florigen gene with different transcription profiles in two cultivars (late-maturing Zigongdongdou and early-maturing Heihe 27) with different maturity profiles, is key to flowering and maturation. However, up to now, its role in the diverse patterns of maturation in soybeans has been poorly understood.

Methods

Eighty varieties, including 19 wild accessions, covering 11 of all 13 maturity groups, were collected. They were planted in pots and maintained under different photoperiodicity conditions (SD, short day; LD, long day; and ND, natural day). The day to first flowering was recorded and the sensitivity to photoperiod was investigated. Polymorphisms in the GmFT2a coding sequence were explored by searching the known SNP database (NCBI dbSNP). The GmFT2a promoter regions were then cloned from these varieties and sequenced. Further polymorphism and association analyses were conducted.

Results

These varieties varied greatly in time to first flowering under ND and exhibited a consecutive distribution of photoperiod sensitivity, which suggested that there is rich diversity in flowering time. Furthermore, although GmFT2a had only one known synonymous SNP in the coding sequence, there were 17 haplotypes of the GmFT2a promoter region, HT06 of which was extremely abundant. Further association analysis found some SNPs that might be associated with day to first flowering and photoperiod sensitivity.

Conclusion

Although GmFT2a is a key flowering gene, GmFT2a polymorphism does not appear to be responsible for maturity diversity in soybean.

SUBMITTER: Jiang B

PROVIDER: S-EPMC3796496 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

GmFT2a polymorphism and maturity diversity in soybeans.

Jiang Bingjun B Yue Yanlei Y Gao Youfei Y Ma Liming L Sun Shi S Wu Cunxiang C Hou Wensheng W Lam Hon-Ming HM Han Tianfu T

PloS one 20131014 10

<h4>Background</h4>Soybean is a short-day crop of agricultural, ecological, and economic importance. The sensitive photoperiod responses significantly limit its breeding and adaptation. GmFT2a, a putative florigen gene with different transcription profiles in two cultivars (late-maturing Zigongdongdou and early-maturing Heihe 27) with different maturity profiles, is key to flowering and maturation. However, up to now, its role in the diverse patterns of maturation in soybeans has been poorly und ...[more]

PMID: 24155962

Similar Datasets

Project description:BackgroundAmong the most powerful barriers to broader inclusion of diverse participants in clinical trials are social determinants of health, trustworthiness of health care providers and research institutions, and competing pressures on potential participants. Nevertheless, current tools to assess organizational capabilities for clinical trial diversity focus primarily on trial infrastructure, rely solely on quantitative self-reported data, and lack meaningful assessment of capabilities related to community engagement.MethodsThe Equitable Breakthroughs in Medicine (EQBMED) initiative developed a holistic, collaborative, site-driven formative model and accompanying assessment to catalog sites' current capabilities and identify opportunities for growth in both conducting industry-sponsored clinical trials and enriching diversity of those trials. The model builds upon prior work and reflects unification of two historically distinct components-research operations and community engagement-since sustainable clinical trial diversity efforts must overcome these silos. Here we present the methodology we used to develop the model and accompanying assessment, describe how findings can support clinical trial diversity efforts, and report findings from early field testing at three U.S. sites.ResultsThe first three sites were diverse in size (e.g., < 250-1 K beds), with varying levels of clinical trial capabilities and community engagement. The maturity assessment laid the foundation for sites to identify and prioritize key areas to advance clinical trial diversity capabilities, and each has made tangible progress. In parallel to completing the assessment with these early sites to understand their maturity and set actionable goals, we also collected their feedback on content validity (e.g., clarity, comprehensiveness, terminology) and feasibility (e.g., ability to collect needed information and data, time required). We describe refinements made to improve the assessment and streamline the process. The EQBMED program will deploy the assessment across various site types (e.g., FQHCs, safety net hospitals) and make further refinements as warranted.ConclusionsStrategic investment in clinical trial diversity requires structured assessment of site maturity as a starting point for collaborative action. We propose the EQBMED maturity model as a first step toward informing efforts to increase representation of diverse populations in clinical research.

Dataset Information

GmFT2a polymorphism and maturity diversity in soybeans.

Background

Methods

Results

Conclusion

Publications

GmFT2a polymorphism and maturity diversity in soybeans.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets